Portola Pharmaceuticals Stock Price - PTLA

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
After Hours
Last Trade
Last $ 27.21 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Portola Pharmaceuticals Inc PTLA NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.34 1.27% 27.21 27.77 26.77 27.13 26.87 00:00:02
Bid Price Ask Price Spread Spread % News
13.94 34.56 20.62 59.66% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
6,583 682,751 $ 27.16 $ 18,544,089 680,983 14.81 - 37.95
Last Trade Time Type Quantity Stock Price Currency
16:44:35 priorref 1,376 $ 27.21 USD

Portola Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.12B 77.82M $ -350.22M -5.31 - 76.84M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 5.00 1.40%

more financials information »

Portola Pharmaceuticals News

Loading Messages....

Latest PTLA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PTLA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week28.2228.5426.7727.75693,575-1.01-3.58%
1 Month27.7931.4126.7728.76747,759-0.58-2.09%
3 Months28.8731.5225.559428.55791,263-1.66-5.75%
6 Months29.0431.7323.9128.23934,415-1.83-6.3%
1 Year19.1337.9514.8127.141,162,5288.0842.24%
3 Years19.0067.1014.8134.491,147,4548.2143.21%
5 Years27.0767.1014.8133.50932,7930.140.52%

Portola Pharmaceuticals Description

Portola Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing novel therapeutics. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. Portola focuses on biomarker or genetic approaches to clinical development that it believes will increase the probability of clinical, regulatory, and commercial success of first-in-class therapies. The company also uses collaborative agreements.


Your Recent History
NASDAQ
PTLA
Portola Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.